|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Nalm 1 Human cell line|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 2 publications below|
Commonly used, FITC conjugates provide relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility.
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation. It is expressed in all B cell precursor leukemias.
Analyte Specific Reagent
Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes.
MHCD1901-4 was used in flow cytometry to characterize the localization and function of STRL33/Bonzo.
|Sharron M,Pöhlmann S,Price K,Lolis E,Tsang M,Kirchhoff F,Doms RW,Lee B||Blood (96:41)||2000|
Double G0/G1 peak in the DNA histogram of aberrant marker positive acute leukemia patients is associated with a poor clinical outcome.
MHCD1901-4 was used in flow cytometry to elucidate the relationship between aberrant marker expression and DNA ploidy in patients with acute leukemia.
|Ek¿io¿lu-Demiralp E,Budak-Alpdo¿an T,Alpdo¿an O,Atalay A,Ratip S,Oz D,Bayik M,Ako¿lu T||Leukemia and lymphoma (33:567)||1999|